New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
13:00 EDTSNSSSunesis price target raised to $15 from $12 at Roth Capital
Roth Capital raised Buy rated Sunesis' price target to $15 from $12 based on positive Phase I/II combination data with vosaroxin in older front line AML patients announced at AACR.
News For SNSS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
10:00 EDTSNSSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:27 EDTSNSSSunesis upgraded at Roth Capital
Subscribe for More Information
06:06 EDTSNSSSunesis upgraded to Buy from Neutral at Roth Capital
Subscribe for More Information
December 10, 2014
10:00 EDTSNSSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:23 EDTSNSSOn The Fly: Pre-market Movers
Subscribe for More Information
06:40 EDTSNSSSunesis upgraded to Buy from Hold at Cantor
Subscribe for More Information
December 8, 2014
13:34 EDTSNSSSunesis announces positive results from ongoing trial of Vosaroxin
Subscribe for More Information
12:40 EDTSNSSOn The Fly: Midday Wrap
Subscribe for More Information
09:29 EDTSNSSSunesis risk/reward attractive, says RBC Capital
RBC Capital believes that the EU could approve Sunesis' vosaroxin drug. The firm says that an EU approval would lift the stock by about 35%, and ir keeps a $3 price target and Sector Perform rating on the shares.
05:51 EDTSNSSSunesis to host conference call
Conference call to discuss results from the Phase 3 VALOR trial of vosaroxin and cytarabine will be held on December 9 at 1:30 pm. Webcast Link
December 7, 2014
16:42 EDTSNSSSunesis announces presentation of Phase 3 VALOR trial results
Subscribe for More Information
December 6, 2014
09:15 EDTSNSSSunesis to hold a meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use